Literature DB >> 19272011

Human alpha-iduronidase gene transfer mediated by adeno-associated virus types 1, 2, and 5 in the brain of nonhuman primates: vector diffusion and biodistribution.

Carine Ciron1, Arnaud Cressant, Françoise Roux, Sylvie Raoul, Yan Cherel, Philippe Hantraye, Nicole Déglon, Bertrand Schwartz, Martine Barkats, Jean-Michel Heard, Marc Tardieu, Philippe Moullier, Marie-Anne Colle.   

Abstract

We have previously demonstrated that delivery of a recombinant adeno-associated virus (rAAV) encoding human alpha-iduronidase (hIDUA) in the putamen and centrum semiovale was feasible and beneficial in a dog model of Hurler's syndrome. In the present study, we investigated the safety and vector diffusion profile of three rAAV serotypes (rAAV2/1, rAAV2/2, and rAAV2/5), encoding hIDUA in the central and peripheral nervous systems of nonhuman primates. Six macaques received the same vector dose injected into the right putamen and the homolateral internal capsule. Neurological examinations were done regularly and showed no detectable clinical consequence of the intracerebral injections. Because transgene IDUA was indistinguishable from endogenous enzymatic activity, we looked for vector diffusion by performing quantitative polymerase chain reaction on serial sections from the brain and spinal cord. We found that global diffusion throughout the brain was not significantly different between the three serotypes. However, rAAV2/1 and rAAV2/5 resulted in higher vector copy numbers per cell than did rAAV2/2, respectively, in the brain and the distal neuronal structures (spinal cord and peripheral nerves).

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19272011     DOI: 10.1089/hum.2008.155

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  27 in total

Review 1.  Gene therapy for metachromatic leukodystrophy.

Authors:  Jonathan B Rosenberg; Stephen M Kaminsky; Patrick Aubourg; Ronald G Crystal; Dolan Sondhi
Journal:  J Neurosci Res       Date:  2016-11       Impact factor: 4.164

2.  Efficient central nervous system AAVrh10-mediated intrathecal gene transfer in adult and neonate rats.

Authors:  J Hordeaux; L Dubreil; J Deniaud; F Iacobelli; S Moreau; M Ledevin; C Le Guiner; V Blouin; J Le Duff; A Mendes-Madeira; F Rolling; Y Cherel; P Moullier; M-A Colle
Journal:  Gene Ther       Date:  2015-01-15       Impact factor: 5.250

3.  Efficient CNS targeting in adult mice by intrathecal infusion of single-stranded AAV9-GFP for gene therapy of neurological disorders.

Authors:  K Bey; C Ciron; L Dubreil; J Deniaud; M Ledevin; J Cristini; V Blouin; P Aubourg; M-A Colle
Journal:  Gene Ther       Date:  2017-04-20       Impact factor: 5.250

Review 4.  A next step in adeno-associated virus-mediated gene therapy for neurological diseases: regulation and targeting.

Authors:  Abdelwahed Chtarto; Olivier Bockstael; Terence Tshibangu; Olivier Dewitte; Marc Levivier; Liliane Tenenbaum
Journal:  Br J Clin Pharmacol       Date:  2013-08       Impact factor: 4.335

Review 5.  Gene therapy in mouse models of huntington disease.

Authors:  Amber L Southwell; Paul H Patterson
Journal:  Neuroscientist       Date:  2011-04       Impact factor: 7.519

6.  Biodistribution and safety assessment of AAV2-GAD following intrasubthalamic injection in the rat.

Authors:  Helen L Fitzsimons; Veronique Riban; Ross J Bland; Jennifer L Wendelken; Christine V Sapan; Matthew J During
Journal:  J Gene Med       Date:  2010-04       Impact factor: 4.565

7.  Merits of combination cortical, subcortical, and cerebellar injections for the treatment of Niemann-Pick disease type A.

Authors:  Jie Bu; Karen M Ashe; John Bringas; John Marshall; James C Dodge; Mario A Cabrera-Salazar; John Forsayeth; Edward H Schuchman; Krystof S Bankiewicz; Seng H Cheng; Lamya S Shihabuddin; Marco A Passini
Journal:  Mol Ther       Date:  2012-07-24       Impact factor: 11.454

8.  Comparative transduction efficiency of AAV vector serotypes 1-6 in the substantia nigra and striatum of the primate brain.

Authors:  Eleni A Markakis; Kenneth P Vives; Jeremy Bober; Stefan Leichtle; Csaba Leranth; Jeff Beecham; John D Elsworth; Robert H Roth; R Jude Samulski; D Eugene Redmond
Journal:  Mol Ther       Date:  2009-12-15       Impact factor: 11.454

9.  Therapeutic response in feline sandhoff disease despite immunity to intracranial gene therapy.

Authors:  Allison M Bradbury; J Nicholas Cochran; Victoria J McCurdy; Aime K Johnson; Brandon L Brunson; Heather Gray-Edwards; Stanley G Leroy; Misako Hwang; Ashley N Randle; Laura S Jackson; Nancy E Morrison; Rena C Baek; Thomas N Seyfried; Seng H Cheng; Nancy R Cox; Henry J Baker; M Begona Cachón-González; Timothy M Cox; Miguel Sena-Esteves; Douglas R Martin
Journal:  Mol Ther       Date:  2013-05-21       Impact factor: 11.454

10.  Whole body correction of mucopolysaccharidosis IIIA by intracerebrospinal fluid gene therapy.

Authors:  Virginia Haurigot; Sara Marcó; Albert Ribera; Miguel Garcia; Albert Ruzo; Pilar Villacampa; Eduard Ayuso; Sònia Añor; Anna Andaluz; Mercedes Pineda; Gemma García-Fructuoso; Maria Molas; Luca Maggioni; Sergio Muñoz; Sandra Motas; Jesús Ruberte; Federico Mingozzi; Martí Pumarola; Fatima Bosch
Journal:  J Clin Invest       Date:  2013-07-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.